Introduction
Signaling through the eosinophil-specific IL-5 receptor (IL-5R) drives the terminal differentiation of committed myeloid progenitors to the eosinophil lineage (1-6), promotes eosinophil survival by blocking apoptosis (7, 8) , primes eosinophils for enhanced functional responses in allergic and parasitic diseases (9) (10) (11) , and induces eosinophil secretion of proinflammatory mediators (12) . IL-5 is primarily a type 2 T cell (13) and mast cell-derived (14) cytokine with actions restricted largely to the eosinophil lineage in humans (15-17), in contrast to eosinophil and B cell lineages in the mouse (1, 18) . The IL-5 receptor has a heterodimeric high-affinity structure composed of an eosinophil-specific IL-5-binding alpha (α) subunit, and a beta (β c ) subunit that is shared with the receptors for IL-3 and GM-CSF (19-21).
IL-5R expression is an early event in the eosinophil hematopoietic program (22,23) and is a prerequisite for the development of eosinophilia, eosinophil activation, and prolonged survival of eosinophils in tissues (24, 25) . Engagement of the IL-5R is critical for entry of multipotential hematopoietic progenitors into the eosinophil developmental program, especially since IL-5 upregulates expression of its own receptor on CD34+ hematopoietic progenitors (23,26,27), and induces a switch in alternative splicing of the α subunit from the soluble to transmembrane form of the receptor (26). The α subunit of the receptor is required both for high affinity ligand binding (28) and for optimal signal transduction (29,30), and is therefore critical to all the lineage-specific actions of IL-5 on human eosinophils. Elucidation of IL-5 signaling pathways is therefore extremely pertinent to understanding the mechanisms involved in regulating both the normal physiologic and proinflammatory activities of the eosinophil in allergic and related immune responses (31). rapidly induces the phosphorylation and activation of Jak1, Jak2 and Lyn (34,37), which then phosphorylate both the α and β c subunits of the IL-5R, resulting in the recruitment and activation of Shc, Grb2, SHP-2, and the Stats, primarily Stat1 and Stat5 (36,42,43). The Janus kinases serve to couple these Stats to IL-5R activation. Previous work suggests that signaling through the cytoplasmic tail of the α chain principally utilizes the JAK2-Stat5 pathway (42,44,45), whereas signaling through the β c chain involves the preferential binding and activation of the phosphatase SHP-2, as well as Shc-Grb2, leading to activation of the Ras-Raf1-MEK-ERK-MAP kinase pathway (43). In addition, IL-5 induces the activation of ERK1/2 and the P38 MAP kinases in eosinophils (46).
The functional relevance of the various IL-5 signaling pathways has recently been evaluated using both pharmacologic and peptide inhibitors, as well as antisense oligonucleotide strategies (31). The Lyn and Jak2 kinases were shown to be important for eosinophil development from bone marrow-derived progenitors (47). These tyrosine kinases, along with the SHP-2 tyrosine phosphatase were also shown to be required for the anti-apoptotic effects of in terms of prolonged eosinophil survival (32,47). In contrast, Lyn and Jak2 did not appear to play any role in eosinophil degranulation or expression of surface adhesion molecules, while the Raf-1 kinase appears necessary for eosinophil activation, secretion and upregulation of adhesion molecule function (32).
In the current report, we provide evidence for the existence of a novel signaling cascade activated by the IL-5 receptor in eosinophils, involving the CrkL adapter. Our data demonstrate that CrkL is tyrosine phosphorylated in an IL-5-dependent manner and forms a signaling complex with Stat5, which is also phosphorylated during IL-5 stimulation. We also demonstrate that IL-5-induces functionally active CrkL/Stat5 signaling complexes in the nucleus that bind a palindromic sequence present in the promoters of certain IL-5-inducible genes, to regulate gene
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Purification of human eosinophils: Blood (150ml) from normal, non-allergic, healthy donors was used to isolate eosinophils following methods originally described by Hansel et al. (54).
Informed consent was obtained according to the guidelines established by the Institutional Review Board of the University of Illinois at Chicago. Sedimentation of erythrocytes was performed at room temperature for 1 hour by mixing 50 ml of peripheral blood with 10ml
Macrodex (6% Dextran 70 in 0.9% Sodium Chloride) and 200µl of 0.5M EDTA. The leukoctyecontaining plasma fraction was harvested, diluted 1:1 with PBS, and overlaid on Ficoll-Paque gradients (35 ml of cell mixture onto 15 ml of Ficoll-Paque 400 (Pharmacia Biotech, Uppsala, Sweden), followed by centrifugation for 30 minutes at room temperature. The granulocyte pellets were harvested, washed with PBS, the remaining erythrocytes lysed using brief exposure to distilled water, and the eosinophils isolated using a Miltenyi MACS CD16 kit to remove neutrophils following the methods described by the manufacturer (Miltenyi Biotec, Auburn, CA) (55). Total cell counts and eosinophil counts were performed using Randolph's stain.
Eosinophil purity was routinely >98% as assessed by differential counts of Wrights'-Giemsa stained cytocentrifuge slides, with eosinophil viability >95% as determined by Trypan Blue dye exclusion. Purified eosinophils were incubated for 30 minutes in the presence or absence of IL-5, and nuclear extracts for gel shift analysis prepared immediately as described below.
IL-5 induction of AML14.3D10 cells: AML14.3D10 cells were split and maintained at 1 x 10 6 /ml one day before each experiment. A total of 2 x 10 7 AML14.3D10 cells were resuspended in 10ml of fresh complete media and stimulated with IL-5 (25 µg/ml) for the indicated times at 37°C. The cells were collected at each time point by immediate centrifugation. In some experiments, the AML14.3D10 cells were first pre-cultured with neutralizing anti-GM-CSF antibody for two days prior to stimulation with IL-5 to block autocrine signaling by GM-CSF produced by these cells in culture (52,53).
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Cell lysis using phosphorylation lysis buffer, immunoprecipitations, and immunoblotting using the enhanced chemiluminescence (ECL) method were performed as previously described (56,57).
Preparation of whole cell and nuclear extracts: Nuclear extracts were prepared using a rapid micropreparation technique for small numbers of cells (58) with minor modifications, including the use of protease inhibitor cocktail tablets (Boehringer Mannheim, Germany), and the addition of PMSF (0.5 mM) and DFP (1mM) to the resuspension and lysis buffers (59, 60) . electrophoresed for one hour at 4°C. Electrophoresis was carried out at 11 V/cm (1.5 h for a 10-cm x 10-cm gel; 2 h for 16 cm x 12-cm gel) in a 4°C cold room. Gels were dried and subjected to autoradiography using either a Molecular Dynamics Storm PhosphorImager or Kodak BioMax film.
Preparation of glutathione-S-transferase fusion proteins and binding studies
Expression constructs (pGEX-CrkL-N-SH3 and pGEX-CrkL-C-SH3) for the production of the GST-CrkL-N-SH3 and GST-CrkL-C-SH3 fusion proteins were kindly provided by Dr. Brian Druker (Oregon Health Sciences University, Portland OR) (61) . Production of the glutathione-Stransferase fusion proteins and binding experiments were performed as previously described (56).
Rap1 activation assays
The activation state of Rap1 was determined essentially as previously described (62) . The pGEX construct for the production of a GST-Ral GDS-RBD fusion protein was kindly provided by Dr. Johannes Bos (Utrecht University, Utrecht, The Netherlands). CrkL was also present in these Stat5 complexes, we performed supershift analyses using an antiCrkL antibody (Figs. 5A, 6 ). Addition of the anti-CrkL antibody supershifted the complexes from both AML14.3D10 eosinophils (Fig. 5A ) and normal peripheral blood eosinophils (Fig. 6 ),
and such supershifting was dose-dependent. As supershift controls, the antibodies to Stat5a and CrkL did not produce any complexes in the absence of the AML14.3D10 nuclear extract ( 
Discussion
In the present study, we provide the first evidence for an involvement of the CrkL adapter in IL-5 signaling in eosinophils, and identify the activation of two IL-5-dependent cascades that involve this protein (Fig. 11) . CrkL is a cellular homologue of the v-crk proto-oncogene (72) and contains one SH2 and two SH3 domains within its structure (73) Our findings also establish that CrkL interacts constitutively, via its N-terminal SH3 domain, with the guanine exchange factor C3G in human eosinophils. In response to IL-5 binding to its receptor and IL-5 induced phosphorylation of CrkL, the guanine exchange activity of C3G is induced and regulates activation of Rap1, as evidenced by the strong IL-5 dependent activation of this GTPase. This is the first evidence for activation of Rap1 in IL-5-stimulated eosinophils.
Rap1 is known to be a substrate for the guanine exchange activity of C3G (85) 
